AZRX - AzurRx BioPharma, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
0.5702
+0.0102 (+1.82%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close0.5600
Open0.5510
Bid0.5600 x 1000
Ask0.6900 x 1100
Day's Range0.5510 - 0.6200
52 Week Range0.3710 - 3.1000
Volume99,689
Avg. Volume482,508
Market Cap15.282M
Beta (5Y Monthly)2.16
PE Ratio (TTM)N/A
EPS (TTM)-0.8920
Earnings DateAug 12, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est5.40
  • ACCESSWIRE

    AzurRx BioPharma to Present at the New York City based Investor Summit on March 25th-26th

    NEW YORK, NY / ACCESSWIRE / March 18, 2020 / AzurRx BioPharma (NASDAQ:AZRX) will be presenting at this year's Spring Investor Summit on March 25 th -26 th . During the current climate of concern, The Spring ...

  • AzurRx BioPharma Receives $1.13 million in 2018 CIR (French Research Tax Credit)
    GlobeNewswire

    AzurRx BioPharma Receives $1.13 million in 2018 CIR (French Research Tax Credit)

    The French R&D tax credit initiative (“Crédit d’Impôt Recherche”, or CIR) gives eligible research-based French companies, which are subject to corporate tax in France, the ability to claim tax relief of up to 30% on costs incurred in R&D activities. “The 30% tax relief on R&D activities provides a significant non-dilutive funding source for our on-going research and clinical trial activities in France and Europe through our AzurRx SAS subsidiary,” said James Sapirstein, the CEO of AzurRx. The Research Tax Credit (CIR) is a tax incentive provided by the French Government to encourage the growth of businesses' competitiveness by favoring research and development (R&D) and innovative activities.

  • AzurRx BioPharma Announces Presentation of Phase II MS1819 Data in Cystic Fibrosis at the 2020 Digestive Disease Week Conference
    GlobeNewswire

    AzurRx BioPharma Announces Presentation of Phase II MS1819 Data in Cystic Fibrosis at the 2020 Digestive Disease Week Conference

    The presentation, entitled: “Results from a Phase 2, Open-Label, Multicenter, 2x2 Cross-over Trial to Assess the Safety and Efficacy of MS1819 in Patients with Exocrine Pancreatic Insufficiency Due to Cystic Fibrosis,” will be delivered by Dr. Michael Konstan, Vice Dean for Translational Research and Professor of Pediatrics at Case Western Reserve University in Cleveland, Ohio. Dr. Konstan will discuss the data from the Company’s Phase II study of MS1819 in patients with cystic fibrosis, which demonstrated safety, a coefficient of fat absorption (CFA) which was similar to the value at the same dose in a prior study in chronic pancreatitis, and positive unexpected findings on the coefficient of nitrogen absorption (CNA).

  • AZRX: EPI Treatment in the News
    Zacks Small Cap Research

    AZRX: EPI Treatment in the News

    By John Vandermosten, CFA NASDAQ:AZRX Infectious Disease With the concerns related to the emergence of the novel coronavirus in the news on a daily basis, attention to animal-sourced product used in medicines has also come in to focus. Fears are also rising related to the transmission of animal viruses passing to humans, similar to what happened in the Avian Flu outbreaks from 2013 to 2017 in

  • AzurRx BioPharma Announces Closing of $6.9 Million Private Placement
    GlobeNewswire

    AzurRx BioPharma Announces Closing of $6.9 Million Private Placement

    Alexander Capital, LP acted as sole placement agent in the Offering. Net proceeds from the Offering will be used to eliminate short- and long-term indebtedness, and for general working capital purposes, including product development. The Offering consisted of Senior Convertible Promissory Notes (the “Notes”) and warrants (the “Warrants”) to purchase shares of the Company’s common stock (the “Common Stock”).

  • Benzinga

    The Week Ahead In Biotech: JPMorgan Healthcare Conference, FDA Panel Reviews Opioid Pain Drugs, I-Mab's IPO

    Activity in the biotech space is likely to pick up this week. Events are likely to be headlined by the annual JPMorgan Healthcare Conference. Biotech stocks closed 2019 with gains, although they underperformed ...

  • AzurRx BioPharma To Present Interim Phase 2 Clinical Study Data for MS1819-SD, in combination with standard PERT for Cystic Fibrosis Patients with Severe Exocrine Pancreatic Insufficiency, at Biotech Showcase 2020 Conference (January 13) in San Francisco
    GlobeNewswire

    AzurRx BioPharma To Present Interim Phase 2 Clinical Study Data for MS1819-SD, in combination with standard PERT for Cystic Fibrosis Patients with Severe Exocrine Pancreatic Insufficiency, at Biotech Showcase 2020 Conference (January 13) in San Francisco

    Initial data from the first five patients indicate positive trends for all primary and secondary safety and efficacy endpoints in AzurRx’s Phase 2 Clinical Study for MS1819-SD,.

  • AzurRx BioPharma to Present at the Biotech Showcase 2020 Conference (January 13th)
    GlobeNewswire

    AzurRx BioPharma to Present at the Biotech Showcase 2020 Conference (January 13th)

    BROOKLYN, N.Y., Jan. 06, 2020 -- AzurRx BioPharma, Inc. (NASDAQ:AZRX) (“AzurRx” or the “Company”), a company specializing in the development of non-systemic, recombinant.

  • AzurRx BioPharma Announces Appointment of Daniel Schneiderman as Chief Financial Officer
    GlobeNewswire

    AzurRx BioPharma Announces Appointment of Daniel Schneiderman as Chief Financial Officer

    NEW YORK, Jan. 03, 2020 -- AzurRx BioPharma, Inc. (NASDAQ: AZRX) (“AzurRx” or the “Company”), a company specializing in the development of non-systemic, recombinant therapies.

  • AZRX: 3Q:19 Review
    Zacks Small Cap Research

    AZRX: 3Q:19 Review

    By John Vandermosten, CFA NASDAQ:AZRX READ THE FULL AZRX RESEARCH REPORT AzurRx BioPharma, Inc. (NASDAQ:AZRX) filed its 2019 third quarter 10-Q with the SEC for the three month period ending September 30, 2019. Highlights for the reporting period and to date include the announcement and first dosing in a new combination trial for patients with severe EPI, the readout from the OPTION trial, the

  • AzurRx BioPharma, Inc. Announces Equity Purchase Agreement for up to $15 Million with Lincoln Park Capital Fund, LLC
    GlobeNewswire

    AzurRx BioPharma, Inc. Announces Equity Purchase Agreement for up to $15 Million with Lincoln Park Capital Fund, LLC

    Under the purchase agreement, AzurRx will have the right to sell up to $15 million of its stock to Lincoln Park over a 30-month period, upon satisfaction of the conditions in the purchase agreement, including after a registration statement registering the resale of shares to be sold to Lincoln Park under the purchase agreement is declared effective by the Securities and Exchange Commission (SEC). AzurRx, from time to time over a 30 month period, will have the right, at its sole discretion, to sell up to $15 million of its stock to Lincoln Park.

  • AzurRx BioPharma CEO Issues Letter to Shareholders
    GlobeNewswire

    AzurRx BioPharma CEO Issues Letter to Shareholders

    AzurRx BioPharma, Inc. (“AzurRx” or the “Company”) (AZRX), a company specializing in the development of non-systemic, recombinant therapies for gastrointestinal diseases, today issued the following letter to its shareholders and the investment community from its newly appointed CEO, James Sapirstein. It is with great pleasure that I am writing to you as the new President and Chief Executive Officer of AzurRx BioPharma, Inc. By way of background, I have over 35 years of pharmaceutical industry experience spanning areas such as drug development and commercialization.

  • AzurRx BioPharma Announces Positive CFF DSMB Review of Final Phase 2 OPTION Trial Data
    GlobeNewswire

    AzurRx BioPharma Announces Positive CFF DSMB Review of Final Phase 2 OPTION Trial Data

    AzurRx BioPharma, Inc. (AZRX) (“AzurRx” or the “Company”), a company specializing in the development of non-systemic, recombinant therapies for gastrointestinal diseases, today announced that the Cystic Fibrosis Foundation (CFF) Data Safety Monitoring Board (DSMB) has completed  its review of the Company’s final results of the Phase 2 OPTION trial and has found no safety concerns for MS1819-SD. Additionally, the group supports the Company’s plan to proceed to a higher 4-gram dose of MS1819-SD in its next planned Phase 2 clinical trial.

  • AzurRx BioPharma Announces First Patients Dosed in Clinical Study for MS1819-SD in combination with PERT for Cystic Fibrosis Patients with Severe Exocrine Pancreatic Insufficiency
    GlobeNewswire

    AzurRx BioPharma Announces First Patients Dosed in Clinical Study for MS1819-SD in combination with PERT for Cystic Fibrosis Patients with Severe Exocrine Pancreatic Insufficiency

    AzurRx BioPharma, Inc. (AZRX) (“AzurRx” or the “Company”), a company specializing in the development of non-systemic, recombinant therapies for gastrointestinal diseases, today announced that it has dosed the first patients in its Phase 2 clinical trial to investigate MS1819-SD in combination with standard porcine enzyme replacement therapy (PERT) for patients with cystic fibrosis (CF) who suffer from severe exocrine pancreatic insufficiency (EPI).

  • AzurRx BioPharma Announces Appointment of James Sapirstein as Chief Executive Officer
    GlobeNewswire

    AzurRx BioPharma Announces Appointment of James Sapirstein as Chief Executive Officer

    AzurRx BioPharma, Inc. (AZRX) (“AzurRx” or the “Company”), a company specializing in the development of non-systemic, recombinant therapies for gastrointestinal diseases, is pleased to announce that James Sapirstein has been appointed to serve as the Company’s President and Chief Executive Officer following the resignation of Thijs Spoor from the same positions. Mr. Sapirstein, who most recently served as chief executive officer and board member for ContraVir Pharmaceuticals, Inc. (now known as Hepion Pharmaceuticals, Inc. (NASADQ:HEPA)), has nearly 36 years of pharmaceutical industry experience spanning areas such as drug development and commercialization.

  • AZRX: OPTION Trial Readout
    Zacks Small Cap Research

    AZRX: OPTION Trial Readout

    By John Vandermosten, CFA NASDAQ:AZRX READ THE FULL AZRX RESEARCH REPORT AzurRx BioPharma, Inc. (NASDAQ:AZRX) announced Phase II OPTION trial results for MS1819 in cystic fibrosis (CF) patients. Data provided was sparse, but the summary highlighted the positive safety profile for MS1819 and the utility of the drug in comparison with porcine enzyme replacement

  • Benzinga

    The Daily Biotech Pulse: Enanta Aces Midstage NASH Study, Takeda's Ulcerative Colitis Drug Found Superior To AbbVie's, Decision Day For J&J

    The following is a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks that hit 52-week highs Sept. 25.) Coherus Biosciences Inc (NASDAQ: CHRS ) The ...

  • Benzinga

    AzurRx Shares Tank On Unimpressive Efficacy Data For Biologic Drug To Treat Pancreatic Insufficiency

    AzurRx is working on developing non-systemic, recombinant therapies for gastrointestinal diseases. The company said the results of the Phase 2 OPTION trial that is evaluating its MS1819 in the treatment of exocrine pancreatic insufficiency in cystic fibrosis showed that the primary efficacy endpoint of coefficient of fat absorption, or CFA, was comparable to that in a previous Phase 2 study in patients with chronic pancreatitis. Despite the study not being powered for statistical significance, the data showed meaningful efficacy results, with about 50% of patients showing CFAs high enough to reach non-inferiority with porcine enzyme replacement therapies, or PERT, AzurRx said.

  • AzurRx BioPharma Announces Positive Results from Phase 2 Trial with MS1819 in Cystic Fibrosis Patients
    GlobeNewswire

    AzurRx BioPharma Announces Positive Results from Phase 2 Trial with MS1819 in Cystic Fibrosis Patients

    Results showed that the primary efficacy endpoint of coefficient of fat absorption (CFA) was comparable to the CFA in a prior phase 2 study in patients with chronic pancreatitis, while using the same dose of MS1819.  The dose used in both studies was 2 gram/day, which was selected in agreement with FDA as a bridging dose. Although the study was not powered for statistical significance, the data also demonstrated meaningful efficacy results, with approximately 50% of the patients showing CFAs high enough to reach non-inferiority with porcine enzyme replacement therapies (PERT).

  • What Kind Of Shareholder Owns Most AzurRx BioPharma, Inc. (NASDAQ:AZRX) Stock?
    Simply Wall St.

    What Kind Of Shareholder Owns Most AzurRx BioPharma, Inc. (NASDAQ:AZRX) Stock?

    A look at the shareholders of AzurRx BioPharma, Inc. (NASDAQ:AZRX) can tell us which group is most powerful. Large...

  • Zacks Small Cap Research

    AZRX: OPTION & Combo Trial Underway

    By John Vandermosten, CFA NASDAQ:AZRX READ THE FULL AZRX RESEARCH REPORT AzurRx BioPharma, Inc. (NASDAQ:AZRX) filed its 2019 second quarter 10-Q with the SEC for the three month period ending June 30, ...

  • AzurRx BioPharma Reports Second Quarter 2019 Financial Results and Provides Corporate Update
    GlobeNewswire

    AzurRx BioPharma Reports Second Quarter 2019 Financial Results and Provides Corporate Update

    AzurRx BioPharma, Inc. (AZRX) (“AzurRx” or the “Company”), a company specializing in the development of non-systemic, recombinant therapies for gastrointestinal diseases, reported financial results for the three and six months ended June 30, 2019 and highlighted recent corporate progress. Announced that the first patients were dosed in an open-label, cross-over Phase II OPTION Study with MS1819-SD for exocrine pancreatic insufficiency (“EPI”) in cystic fibrosis (“CF”) in February 2019 and that the study enrollment target was met in May 2019. The Company continues to expect results from the study in September 2019.

  • ACCESSWIRE

    AzurRx BioPharma Announces Closing of $5.0 Million Public Offering of Common Stock

    BROOKLYN, NY / ACCESSWIRE / July 22, 2019 / AzurRx BioPharma (AZRX), (“AzurRx” or the “Company”), today announced the closing and funding of its previously announced underwritten public offering of five million shares of its common stock at a price to the public of $1.00 per share. The Company also granted the underwriters a 30-day option to purchase up to 750,000 additional shares of common stock, at the public offering price, less underwriting discounts and commissions.

  • ACCESSWIRE

    AzurRx BioPharma Announces Pricing of $5.0 Million Public Offering of Common Stock

    BROOKLYN, NY / ACCESSWIRE / July 17, 2019 / AzurRx BioPharma (AZRX), (“AzurRx” or the “Company”), today announced the pricing of its previously announced underwritten public offering of five million shares of its common stock at a price to the public of $1.00 per share. AzurRx expects to receive aggregate gross proceeds of $5.0 million from the offering. The offering is expected to close on or about July 22, 2019, subject to customary closing conditions.

  • AzurRx BioPharma Announces Proposed Public Offering of Common Stock
    GlobeNewswire

    AzurRx BioPharma Announces Proposed Public Offering of Common Stock

    H.C. Wainwright & Co. is acting as the sole book-running manager for the offering.  National Securities Corporation, a wholly owned subsidiary of National Holdings Corporation (NHLD), is acting as a co-manager for the offering.